

16.07.98

PTNL 98/00259

09/423838



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

REC'D	05 AUG 1998
WIPO	PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

97201423.7

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts:
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

M. B. BJLING

DEN AAG N
THE GUE 20/05/98
LA H T, LE



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation

Anmeldung Nr.:
Application no.: 97201423.7
Demande n°:

Anmeldetag
Date of filing 12/05/97
Date de dépôt

Anmelder:
Applicant(s):
Demandeur(s):
NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO
2628 VK Delft
NETHERLANDS

Bezeichnung der Erfindung
Title of the invention
Titre de l'invention

Method and construct for inhibition of cell migration

In Anspruch genommene Priorität(en) / Priorities claimed / Priorité(s) revendiquée(s)

Staat
State
Pays

Tag
Date
Date

Aktenzeichen
File no
Numero de dépôt

Internationale Patentklassifikation
International Patent classification
Classification internationale des brevets

C12N9/72, C12N15/62, C07K14/81, // C07K19/00

Am Anmeldetag benannte Vertragsstaaten
Contracting states designated at date of filing AT/BE/CH/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE
Etats contractants désignés lors du dépôt

Bemerkungen
Remarks
Remarques

3

Title: Method and Construct for inhibition of cell migration

FIELD OF THE INVENTION

The invention is in the field of therapeutic means and therapeutic methods for treatment of diseases in which cell migration and/or tissue remodeling occurs. Furthermore, the invention is in the field of biotechnology, in particular recombinant DNA technology and gene therapy.

BACKGROUND OF THE INVENTION

Migration of cells is an essential step in many physiological and pathological processes in which tissue remodeling occurs, such as tumor metastasis, wound healing, restenosis, angiogenesis or rheumatic arthritis. Migrating cells have to pass through the surrounding extracellular matrix. Limited proteolytic degradation of the components of the extracellular matrix is often seen during cell migration. To mediate this cell migration migrating cells produce, or recruit from their direct environment, proteolytic enzymes, such as plasminogen activators, metalloproteinases or elastases. Induction of cell migration e.g. during tumor metastasis or wound healing often correlates with the induction of the production of these enzymes.

Although the involvement of proteolytic enzymes in cell migration under pathophysiological conditions is well accepted, little attempts have been made to inhibit cell migration by inhibiting these proteolytic enzymes. A possible explanation for the limited use of protease inhibitors is the fact that these proteolytic enzymes are involved in many processes both pathological and physiological (including fibrinolysis, wound healing, growth factor activation etc.) and that inhibition of these protease systems by systemically applied protease inhibitors might have either strong side effects or may lead to a diffusion or clearance of the inhibitory compounds without having a strong effect on the local cell migration processes.

Another problem in the use of protease inhibitors to interfere in cell migration and tissue remodeling is that proteases mediating these processes can bind to receptors at the cell surface. In this way the proteolytic enzymes might be active locally in a pericellular microenvironment where they are protected against the action of the present inhibitors.

It has been disclosed that conjugates between the receptor binding part of u-PA (the aminoterminal fragment or ATF) and urinary trypsin inhibitor produced in vitro, inhibit migration of tumor cells in vitro (Kobayashi, Gotoh, Hirashima, Fujie, Sugino and Terao, Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro. J. Biol. Chem. (1995) 270, 8361-8366). The conjugate these authors have used is made synthetically by mixing the isolated ATF fragments with the trypsin inhibitor.

A comparable construct consisting of a receptor binding u-PA fragment and its inhibitor PAI-2, to be produced recombinantly in yeast, has been described to inhibit tumor cell migration in WO 92/02553 (PCT/GB91/01322). In this way they have made a protease inhibitor that can bind to a specific receptor at the cell surface, the urokinase receptor, and this inhibitor can inhibit cell migration (in vitro). As to the use of these constructs in vivo, a problem is the application to and the prolonged presence at the site of desired action in vivo.

SUMMARY OF THE INVENTION

This invention provides a recombinant nucleic acid molecule comprising a vector useful for transfection or transduction of mammalian, e.g. human, cells, wherein said vector contains a nucleic acid insertion encoding an expressible hybrid polypeptide or protein which comprises a domain with a binding function and a domain with an effector function. Herein, the domain with a binding function

preferably comprises a receptor binding domain, and the domain with an effector function preferably has enzymatic activity, most preferably protease inhibitor activity.

Preferably, the receptor binding domain is selected from the group consisting of urokinase receptor binding domain of urokinase, receptor binding domain of epidermal growth factor, receptor associated protein that binds to LDL Receptor related protein (α_2 -macroglobulin receptor) and VLDL Receptor.

Preferably, the domain with an effector function has protease inhibitor activity and comprises a protease inhibitor or active part thereof, said protease inhibitor being selected from the group consisting of (bovine) pancreatic trypsin inhibitor, (bovine) splenic trypsin inhibitor, urinary trypsin inhibitor, tissue inhibitor of matrix metalloproteinase 1, tissue inhibitor of matrix metalloproteinase 2, tissue inhibitor of matrix metalloproteinase 3, and elastase inhibitor. The domain with an effector function may comprise (an active part of) two or more different protease inhibitors, or two or more copies of (an active part of) a protease inhibitor, or both.

Preferably, the vector is selected from the group consisting of viral and non-viral vectors useful for transfection or transduction of mammalian cells. The vector may be an adenovirus vector or a retrovirus vector useful for transfection or transduction of human cells.

The nucleic acid insertion encoding an expressible hybrid polypeptide or protein may be under the control of a cell- or tissue-specific promoter, such as an endothelial cell-specific promoter, or a vascular smooth muscle cell-specific promoter, or a liver-specific promoter.

This invention furthermore provides a process for preventing local proteolytic activity, extracellular matrix degradation, cell migration, cell invasion, or tissue remodeling, comprising transfecting or transducing the cells involved or cells in their environment with a recombinant

nucleic acid molecule as defined herein to obtain local expression of the hybrid polypeptide or protein encoded by said nucleic acid molecule.

Also, this invention provides a process for
5 producing a hybrid polypeptide or protein which comprises a domain with a binding function and a domain with an effector function, comprising transfecting or transducing mammalian cells with a recombinant nucleic acid molecule as defined herein to obtain expression of the hybrid polypeptide or
10 protein encoded by said nucleic acid molecule, and optionally recovering the hybrid polypeptide or protein produced.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 schematically depicts the plasmids pCRII-uPA (left) and pCRII-ATF (right).
15

Figure 2 schematically depicts the plasmid pCRII-ATF-BPTI.

Figure 3 schematically depicts the plasmid pMAD5-ATF-BPTI.

20 Figure 4 shows the results of proteolytic matrix degradation experiments.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to the use of hybrid
25 proteins in which a receptor binding domain is linked to a functional protein in order to induce a local action of this protein and to prevent systemic effects and/or diffusion. In particular this invention relates to such hybrid proteins that might be produced by a subset of cells as target cells
30 after transfection or transduction with expression vectors. More specifically the invention relates to the use of such expression vectors, coding for hybrid proteins consisting of a receptor binding domain and a protease inhibitor domain, for the prevention of cell migration and tissue remodeling by
35 inhibition of proteases at the surface of migrating or invading cells.

The method and construct described in the present invention can be applied as therapy in diseases in which cell migration and/or tissue remodeling occurs.

The present invention addresses the solution of several negative aspects involved in the above described use of inhibitors according to the prior art:

- High local concentrations of hybrid proteins in the direct environment of the target cells can be obtained by production of the protein by the migrating cells themselves or cells in their immediate environment. This production can be induced by transfection or transduction of a certain subset of the cell population with a suitable vector encoding the hybrid protein. For this purpose, one may use recombinant adenoviral vectors, retroviral vectors, plasmid vectors, etc.

- Diffusion of the inhibitor and systemic side effects are prevented by binding the hybrid protein (by its receptor binding domain) to the cell surface of the target cell. Local expression of this hybrid protein also contributes to the reduction of systemic side effects, while the negative effect of diffusion of the protein is reduced by the production at the site where action is required. The local expression of the hybrid protein in specific sub-populations of cells, e.g. endothelial cells prone to migrate during angiogenesis, can be enhanced using cell type-specific or tissue-specific expression vectors, in which the expression of the protein is under control of a promoter with cell type-specific or tissue-specific regulatory elements.

- Binding of a protease inhibitor to a cell surface receptor can locate the inhibitor close to its molecular target, the cell surface bound proteolytic enzyme. Local inhibition of the proteolytic activity in the pericellular microenvironment may be achieved in this way.

- Binding of a protease inhibitor to a cell surface receptor for a proteolytic enzyme, such as the urokinase receptor, may have an additional inhibitory effect. It prevents the binding of the proteolytic enzyme to its

receptor, and thus strongly reduces the action of this enzyme as has been shown for blocking the binding of u-PA to its receptor which can strongly inhibit cell migration.

Hybrid proteins, for which the expression vectors
5 (e.g. adenoviral or retroviral expression vectors) contain the encoding DNA sequences, might contain a region that binds to a cell surface receptor and that is not subsequently internalized. Receptor binding domains that can be used for this purpose are e.g. the u-PAR binding domain of urokinase
10 plasminogen activator, the receptor binding domain of epidermal growth factor, the receptor associated protein (RAP) that binds to the LDL-R related protein (LRP), also called α_2 -macroglobulin receptor, and the VLDL-receptor.

The inhibitor part of the encoded hybrid protein
15 might consist of various protease inhibitors such as bovine pancreatic trypsin inhibitor, also called aprotinin or Trasylol[®], other trypsin inhibitors such as urinary trypsin inhibitor, inhibitors for matrix-degrading metalloproteinases such the tissue inhibitors of metalloproteinases TIMP-1,
20 TIMP-2 and TIMP-3, or variants thereof. Also inhibitors for other proteases like elastase are very suitable for being incorporated into the expression vector containing the DNA sequences encoding the hybrid proteins. Multiple copies of the DNA sequences encoding the functional protein part of the
25 hybrid protein e.g. the inhibitor part, or combinations of different inhibitors or derivatives thereof might be incorporated into the DNA construct in the expression vector.

Another very attractive possibility would be to use such an expression vector encoding hybrid receptor binding
30 protein to apply any functional protein that should exert its action in the local environment of the target cell, e.g. a protease involved in the activation of a growth factor or an other e.g. vasoregulatory component.

The action of the functional protein or protein
35 domains of the hybrid protein is localized to the direct microenvironment of the target cells by binding of the

receptor binding domain to a receptor at the surface of the target cells. Production of the hybrid protein in the direct environment of the target cells or even by the target cells themselves can be obtained by transfection or transduction of these cells by the use of expression vectors that might be based on a non-viral or an adeno- or retroviral vector system. Expression in specific cell or tissue types might be achieved by the use of specific promoter elements in the expression vectors. For example, for endothelial cell-specific expression (elements of) the promoter region of the human or murine pre-pro-endothelin gene (HUMEDN1B and MMU07982, respectively, GENBANK) can be used, for vascular smooth muscle cell-specific expression (elements of) the promoter region of the human vascular smooth muscle α -actin gene (HUMACTSA, GENBANK) can be used, and for liver-specific expression the promoter of the human albumin gene (HUMALBGC, GENBANK) can be used.

Local delivery of these vectors might be obtained using various commonly used methods, including catheters, topically applied gels containing the vectors or targeted delivery systems. For site-specific delivery to the vessel wall, e.g. to prevent restenosis and vessel wall remodeling after angioplasty, special catheters can be used. At the moment double balloon catheters, channeled balloon catheters, multiple needle catheters and balloon catheters coated with a vector containing a hydrogel are being used for vessel wall-specific delivery. Other ways to deliver the vectors directly into the vessel wall are the use of stents coated with vector containing coatings, topical application of vector containing hydrogels to the outside of the blood vessel or ex vivo delivery directly into the blood vessel during transplantation surgery. Ex vivo transduction of proliferating cells using retroviral vectors followed by a reinjection may also be used to deliver the vector constructs at the site where their action is required.

The present application will be described herein-
after in further detail, while referring to the following
examples. It is to be noted that these examples merely serve
to illustrate the invention, not to restrict it.

5

EXAMPLE 1

An expression plasmid encoding the aminoterminal
fragment of urokinase plasminogen activator (u-PA), amino
acids 1-138, hereafter referred to as ATF, can be constructed
10 by deleting the DNA sequences encoding amino acids 139 till
401 in an expression plasmid for the full length u-PA using a
polymerase chain reaction (PCR) with the following oligo-
nucleotides: 5'-cccgggcttttttccatctgcgcagtc-3' and
5'-agggtcaccaaggaagaagaatggc-3'. After amplification by PCR
15 the newly formed DNA fragment can be circularized by ligation
to restore the circular character of the expression plasmid.
In this way an expression plasmid encoding the ATF and the C
terminal last 11 amino acid residues including the stop codon
can be constructed.

20

The sequence of the thus formed DNA construct enco-
ding the u-PA ATF fragment then is determined and compared
with the predicted sequence as a control for possible
mutations introduced during the construction procedure.

25

The construction pCRII-ATF from pCRII-uPA using PCR
is shown in Figure 1. In figure 1, the area indicated between
the lines was removed during the PCR amplification, resulting
in the ATF plasmid. The plasmid pCRII-uPA is shown to the
left, plasmid pCRII-ATF to the right.

30

EXAMPLE 2

35

DNA fragments encoding amino acid residues 36-93 of
bovine pancreatic trypsin inhibitor (BPTI) and the homologous
amino acid residues of bovine spleen trypsin inhibitor (BSTI)
can be isolated by performing a PCR reaction on genomic DNA
isolated for bovine aortic endothelial cells using the
following oligonucleotides: 5'-tgcgcacctgacttctgcctagagc-3'

covering nucleotides 2509 to 2533 (with modifications, indicated in *italics*, in the 5' region of the oligonucleotide to introduce a NruI site (underlined) for cloning purposes) of the BPTI gene according to the published sequence (GENBANK, BTBPTIG), and nucleotide 2442 to 2462 of the BSTI gene according to the published sequence (GENBANK, BTBSTIG) and 5'-ggtcaccccagggcccaatattaccacc-3' covering nucleotides 2677 to 2704 of the BPTI gene and 2610 to 2636 of the BSTI gene (modified in the indicated nucleotides (*italics*) to introduce a BstEII and a SspI site respectively (underlined)). The amplified DNA fragments then were cloned into an appropriate plasmid vector, pCRII or pUC13, and then the exact sequence of the amplified DNA fragments in the isolated clones was analyzed to differentiate between BPTI and BSTI which have a very high degree of homology.

EXAMPLE 3

The DNA fragment encoding amino acids 1 to 207 of the human tissue inhibitor of metalloproteinase type 1 is isolated by performing a reverse transcriptase polymerase chain reaction on total RNA isolated from human foreskin fibroblasts by using the following oligonucleotides 5'-agagagacaccagagaacccaccat-3' covering nucleotides 41 to 65 of the human TIMP-1 cDNA (according to the sequence in GENBANK HSTIMPR) and 5'-tcattgtccggaagaaagatgggag-3' covering nucleotides 740 till 755. The amplified DNA fragment was cloned into an appropriate host vector, pUC13, and then the exact sequence of the amplified DNA fragment in the isolated clones was analyzed.

EXAMPLE 4

For construction of a recombinant adenovirus containing sequences encoding the ATF.BPTI hybrid protein, this sequence is cloned in the adenoviral vector construction adapter and expression plasmid pMAD5. This plasmid contains part of the wildtype adenovirus type 5 DNA sequences, a Major

Late Promoter (MLP), and a poly-adenylation (polyA) signal and can be used as either an expression vector or a shuttle vector to construct a recombinant adenovirus. This plasmid was derived from plasmid pMLP10 as follows. First pMLP10-lin
 5 was constructed by insertion of a synthetic DNA fragment with unique sites for the restriction endonucleases MluI, SplI, SnaBI, SpeI, AsuII and MunI into the HindIII site of pMLP10. Subsequently, the adenovirus BglII fragment spanning nt 3328 to 8914 of the Ad5 genome was inserted into the MunI site of
 10 pMLP10-lin. Finally, the SalI-BamHI fragment was deleted to inactivate the tetracycline resistance gene, resulting in plasmid pMAD5. To clone the ATF.BPTI sequence into the pMAD5 plasmid between the MLP promoter and the polyA signal the following strategy has been followed.

15 Starting from a pCRII plasmid in which a 1373 base pair fragment of the uPA cDNA was cloned, a PCR reaction with the oligonucleotides 5'-cccgggcttttttccatctgcgcagtc-3' (SmaI site underlined and nucleotides changed in *italics*) and 5'-aggggtcaccaaggaagagaatggc-3' (BstEII site underlined and
 20 nucleotides changed in *italics*) was performed as described in example 1 to make a pCRII-ATF plasmid (see figure 1). Subsequently this pCRII-ATF plasmid was digested with the restriction enzymes SmaI and BsteII. In parallel the pCRII-BPTI plasmid was digested with the restriction enzymes NruI
 25 and BsteII and the BPTI containing fragment was cloned into the pCRII-ATF plasmid (see figure 2). The construction pCRII-ATF-BPTI is shown in Fig. 2.

In a next step the ATF-BPTI sequence was cloned into pMAD5. This was done by digestion of the pCRII-ATF-BPTI
 30 plasmid with the restriction enzymes EcoRV and SpeI, isolation of the ATF-BPTI encoding DNA fragment and cloning of this fragment into the SnaBI and SpeI digested pMAD5 plasmid. The cloning was tested by restriction analysis and sequence analysis.

35 The pMAD5-ATF-BPTI shuttle vector for the construction of ATF-BPTI adenoviral vector is shown in Figure 3.

EXAMPLE 5

In a similar way as described in example 4 for pMAD5-ATF-BPTI a plasmid containing the BSTI-gene (pMAD5-ATF-BSTI) was constructed using the pCRII-BSTI plasmid instead of
5 the pCRII-BPTI plasmid.

EXAMPLE 6

For construction of a recombinant adenovirus containing sequences encoding the ATF-TIMP1 hybrid protein,
10 this sequence is cloned in the pMAD5 expression plasmid. This plasmid contains part of the wildtype adenovirus type 5 DNA sequences, a Major Late Promoter (MLP), and a polyadenylation (polyA) signal and can be used as either an expression vector or a shuttle vector to construct a recombinant adenovirus. To
15 clone the ATF-TIMP1 sequence into the pMAD5 plasmid between the MLP promoter and the polyA signal, the following strategy has been followed.

Starting from a pCRII plasmid in which a 1373 base pair fragment of the uPA cDNA was cloned, a PCR reaction with
20 the oligonucleotides 5'-cccggtctttttccatctgcgcagtc-3' and 5'-agggtcaccaaggaagagaatggc-3' was performed as described in example 1 to make a pCRII-ATF plasmid (see figure 1). Subsequently this pCRII-ATF plasmid was digested with the restriction enzymes SmaI and BstEII.

In parallel a fragment of the cDNA of TIMP1 in pUC13-TIMP1 encoding amino acid residues 1 to 184 of the mature protein, but lacking the signal peptide and the stop codon, was amplified using the following oligonucleotides
25 5'-tcgcatgcacctgtgtcccacc-3' and
30 5'-ggtcacccaaatattggctatgtgggaccgcaggg-3'. These oligonucleotides contain recognition sites for the restriction enzymes NruI (first oligonucleotide, underlined) and BstEII and SspI respectively (second oligonucleotide, underlined); these sites are needed for the cloning procedure.

35 The amplified DNA fragment was cloned into a pCRII vector and called pCRII-TIMP1. This vector was subsequently

digested with the restriction enzymes NruI and BstEII and the TIMP1 containing DNA fragment was cloned into the pCRII-ATF plasmid (see figure 1).

5 In a next step the ATF-TIMP sequence was cloned into pMAD5. This was done by digestion of the pCRII-ATF-TIMP plasmid with the restriction enzymes EcoRV and SpeI, isolation of the ATF-TIMP encoding DNA fragment and cloning of this fragment into the SnaBI and SpeI digested pMAD5 plasmid. The cloning was tested by restriction analysis and
10 sequence analysis.

EXAMPLE 7

Vectors encoding hybrid proteins containing multiple copies of the BPTI unit coupled to the ATF domain
15 have been constructed. To construct these multiple BPTI vectors, the following strategy is followed.

The pMAD5-ATF-BPTI described in EXAMPLE 4 is digested with the restriction enzymes SspI and BstEII. In this way the vector is opened exactly in the open reading
20 frame at the end of the BPTI sequence. The pCRII-BPTI plasmid described in EXAMPLE 2 is digested with NruI and BstEII resulting in a BPTI encoding DNA fragment with one blunt end (NruI). The fragment was then monodirectionally cloned into the SspI BstEII pMAD5-ATF-BPTI vector. The thus constructed
25 plasmid named pMAD5-ATF-BPTI-BPTI was used as a shuttle vector for the construction of recombinant adenoviruses.

This approach can be repeated multiple times to construct vectors containing multiple BPTI-domains.

30 EXAMPLE 8

A vector encoding a hybrid protein containing both a BPTI unit and a TIMP1 unit coupled to the ATF domain has been constructed. To construct this BPTI-TIMP vector, the following strategy is followed.

35 The pMAD5-ATF-BPTI described in EXAMPLE 4 is digested with the restriction enzymes SspI and BstEII. In

this way the vector is opened right behind the BPTI sequence. The pCRII-TIMP plasmid described in EXAMPLE 6 is digested with NruI and BstEII resulting in a TIMP1 encoding DNA fragment with one blunt end. The fragment was then cloned into the SspI BstEII pMAD5-ATF-BPTI vector. The thus constructed plasmid named pMAD5-ATF-BPTI-TIMP was used as a shuttle vector for the construction of recombinant adenoviruses.

EXAMPLE 9

To monitor the production of a functional ATF-BPTI hybrid protein after transfection of cells with pMAD5 or transduction with a recombinant replication-deficient ATF-BPTI encoding adenovirus, the following tests have been performed.

- The production of the hybrid ATF-BPTI protein by CHO cells transfected with the pMAD5-ATF-BPTI was analyzed using a uPA ELISA that recognizes the ATF, the aminoterminal fragment of u-PA. Production of ATF-BPTI was clearly detectable both after transient transfection of CHO cells with the pMAD5-ATF-BPTI plasmid (50-100 ng/ml/24hrs) and after transduction with an ATF-BPTI encoding adenoviral vector (up to 1.5 µg/ml/24hrs).

- The cell culture media of CHO cells transduced with the ATF-BPTI adenovirus were analyzed using western blotting techniques. After electrophoresis and blotting, parallel filters were analyzed with polyclonal antibodies against either u-PA or BPTI (raised against Trasylol®). In both filters a signal was detected at the same expected position at approximately 20kDa. This indicates that the protein produced indeed contains fragments of u-PA and BPTI, thus that the hybrid protein is produced.

- The function as an inhibitor of plasmin activity of the ATF-BPTI protein was first analyzed in solution using dilutions of the culture medium of ATF-BPTI virus infected CHO cells (approximately 1.8 µg/ml). They were incubated with plasmin (1 nM) and the activity of plasmin was measured using

a chromogenic substrate. Trasylol® dilutions were used as control references. Plasmin inhibition by ATF-BPTI medium was very effective, diluting the medium 1000x (i.e. 100 nM ATF-BPTI) resulted in a 50% inhibition of the activity of 1 nM plasmin, a similar inhibition as was observed with 100 nM Trasylol®. Thus the activity of ATF-BPTI is comparable to that of commercially available Trasylol® (Bayer, Germany).

- The function of ATF-BPTI as an inhibitor for plasmin bound to the cell surface via the interaction of the ATF domain with the u-PA receptor (uPAR) was tested using mouse cell lines that are either or not transfected with the human uPA receptor gene. These cells were incubated for 6 hrs with diluted medium of the ATF-BPTI virus-infected CHO cells. Cell extracts were made of the uPAR-transfected cells and the parental mouse cells lacking the human uPAR. Parallel cultures underwent a short acid treatment (pH 3, 3 min) before the cell extracts were made. This treatment will remove any u-PA or ATF bound to the u-PA receptor. The cell extracts were incubated with 1nM plasmin and the plasmin activity was determined. Plasmin activity could only be inhibited by the cell extract of the u-PAR containing cell line. No inhibition of plasmin activity was observed in the cell extracts of parental cell line, lacking the u-PA receptor, and in the acid-treated u-PAR containing cell line. This clearly indicates that ATF-BPTI can function as a u-PAR bound plasmin inhibitor.

TABLE 1

	% INHIBITION OF PLASMIN ACTIVITY			
cell line	uPAR transfected cell line		parental cell line	
acid treatment	-	+	-	+
% inhibition	93%	0%	0%	0%

EXAMPLE 10

Cell-specific expression of ATF-BPTI in endothelial cells e.g. to specifically inhibit the migration of endothelial cells during angiogenesis, is achieved by cloning sequences of the promoter of the human pre-pro-endothelin 1 gene (nucleotide 2180-3680 of HUMEDN1B (GENBANK)) in front of the ATF-BPTI encoding DNA in an adenoviral vector. In this way, highly endothelial cell-specific expression of the ATF-BPTI hybrid protein can be obtained.

EXAMPLE 11

Proteolytic degradation of the extracellular matrix is a key event in many cell migration and tissue remodeling processes. This proteolytic matrix degradation is often found to be mediated by urokinase-type plasminogen activation. In order to test whether infection with an ATF-BPTI encoding adenovirus can inhibit plasmin mediated extracellular matrix degradation, an experiment was performed using human synoviocytes. These cells were infected with an ATF-BPTI adenovirus while they were seeded on an ³H-labeled extracellular matrix existing of bovine cartilage material. Profound inhibition of matrix degradation could be observed in the virus treated cells (figure 4) indicating that matrix degradation can be inhibited by infecting cells with the ATF-BPTI encoding virus.

Figure 4 shows the degradation of cartilage matrix by human synoviocytes in the presence of plasminogen. Matrix is incubated with control medium (lane 1), synoviocytes (lane 2), synoviocytes infected with ATF-BPTI adenovirus (lane 3), and synoviocytes incubated with Trasylol® (100KIU/ml) (lane 4).

EXAMPLE 12

In the process of restenosis smooth muscle cell migration and vessel wall remodeling are key events in which plasmin mediated proteolysis of extracellular matrix components is involved. In vivo application of general

plasmin inhibitors to interfere in this process may have systemic side effects. Application of a plasmin inhibitor to the surface of the migrating cells might prevent these side effects. Infection of the blood vessel wall with an ATF-BPTI adenovirus at a site where neointima formation can be expected, e.g. in a transplanted "coronary by-pass" graft, might be a ideal way to produce the ATF-BPTI locally, and thus inhibit plasmin activity in the direct surroundings of the migrating (smooth muscle) cells, resulting in a reduced neointima formation.

This principle was tested using human saphenous vein organ cultures, a model system in which neointima formation can be mimicked very realistically. In parallel cultures, either or not infected with an ATF-BPTI adenovirus, the neointima formation was analyzed after three and four weeks. In the untreated tissues a clear neointima formation could be observed. Profound inhibition of the neointima formation could be observed in the tissues treated with 10^{10} pfu/ml ATF-BPTI adenovirus.

Appendix

Description and Nucleotide sequence of the pMAD5-ATF-BPTI plasmid.

5

From	To	Description
1	184	adenovirus sequence 5'
184	447	adenovirus Major Late Promoter (MLP)
447	644	tripartite leader sequence (TPL)
685	1167	urokinase ATF sequence
1168	1353	bovine pancreas trypsin inhibitor sequence
1360	1443	urokinase 3' sequence (including stop codon)
1514	1615	sequence derived from pSP65 and LacZ
1616	1751	SV40 poly A signal
1752	7334	adenovirus sequence 3'
9831	3971	β -lactamase

20 Nucleotide sequence:

```

1      CATTTTCGCG GGAAACTGA ATAAGAGGAA GTGAATCTG AATAATTTTG TGTTACTCAT
61     AGCGCGTAAT ATTTGTCTAG GGCGCGGGG ACTTTGACCG TTTACGTGGA GACTCGCCCA
121    GGTGTTTTTC TCAGGTGTTT TCGCGGTTCC GGGTCAAAGT TGGCGTTTTA TTATTATAGT
25     181     CAGCTGATCG AGCGGTGTTT CGCGGTCTTC CTCGTATAGA AACTCGGACC ACTCTGAGAC
241    GAAGGCTCGC GTCCAGGCCA GCACGAAGGA GGCTAAGTGG GAGGGGTAGC GGTCTGTGTC
301    CACTAGGGGG TCCACTCGCT CCAGGGTGTG AAGACACATG TCGCCCTCTT CGGCATCAAG
361    GAAGGTGATT GGTTTATAGG TGTAGGCCAC GTGACCGGGT GTTCCTGAAG GGGGGCTATA
421    AAAGGGGGTG GGGGCGCGTT CGTCTCACT CTCTTCCGCA TCGCTGTCTG CGAGGGCCAG
30     481     CTGTTGGGGC TCGCGGTTGA GGACAACTC TTCGCGGTCT TTCCAGTACT CTTGGATCGG
541    AAACCCGTCG GCCTCCGAC GGTACTCCGC CACCGAGGGA CCTGAGCGAG TCCGCATCGA
601    CCGGATCGGA AAACCTCTCG AGAAAGGCGT CTAACCAAGT GCTGATCGAT AAGCTAGCTT
661    ACGCGTACAT CTGCAGAATT CGGCTTAAC CTAGACCATG AGAGCCCTGC TGGCGCGCCT
721    GCTTCTCTGC GTCCTGGTCG TGAGCGACTC CAAAGGCAGC AATGAACTTC ATCAAGTTCC
35     781     ATCGAACTGT GACTGTCTAA ATGGAGGAAC ATGTGTGTCC AACAAGTACT TCTCCAACAT
841    TCACTGGTGC AACTGCCCAA AGAAATTCGG AGGGCAGCAC TGTGAAATAG ATAAGTCAAA

```

901 AACCTGCTAT GAGGGGAATG GTCACCTTTTA CCGAGGAAAG GCCAGCACTG ACACCATGGG
 961 CCGGCCCTGC CTGCCCTGGA ACTCTGCCAC TGTCCTTCAG CAAACGTACC ATGCCCACAG
 1021 ATCTGATGCT CTTCAGCTGG GCCTGGGGAA ACATAATTAC TGCAGGAACC CAGACAACCG
 1081 GAGGCGACCC TGGTGCTATG TGCAGGTGGG CCTAAAGCCG CTTGTCCAAG AGTGCATGGT
 5 1141 GCATGACTGC GCAGATGGAA AAAAGCCCCG ACCTGACTTC TGCCTAGAGC CTCCATATAC
 1201 GGGTCCCTGC AAGGCCAGAA TTATCAGATA CTTCTACAAC GCCAAGGCTG GGCTCTGCCA
 1261 GACCTTTGTA TATGGCGGCT GCAGAGCTAA AAGAAACAAT TTCAAGAGCG CAGAGGACTG
 1321 CATGAGGACC TGTGGTGGTA ATATTGGGCC CTGGGTCACC AAGGAAGAGA ATGGCCTGGC
 1381 CCTCTGAGGG TCCCCAGGGA GGAAACGGGC ACCACCCGCT TTCTTGCTGG TTGTCAATTT
 10 1441 TGCTCTAGAG TCAAGCCGAA TTCTGCAGAT ATCGTCCATT CCGACAGCAT CGCCAGTCAC
 1501 TATGGCGTGC TGCTAGAGGA TCCCCGGGCG AGCTCGAATT CCAGCTGAGC GCCGGTCTGCT
 1561 ACCATTACCA GTTGGTCTGG TGTCAAAAAT AATAATAACC GGGCAGGGGG GATTCTGAAC
 1621 TTGTTTATTG CAGCTTATAA TGGTTACAAA TAAAGCAATA GCATCACAAA TTTCACAAAT
 1681 AAAGCATTTT TTCTACTGCA TTCTAGTTGT GGTTFGTCCA AACTCATCAA TGTATCTTAT
 15 1741 CATGTCTGGA TCTGGPAGGT GCTGAGGTAC GATGAGACCC GCACCAGGTG CAGACCCTGC
 1801 GAGTGTGGCG GTAAACATAT TAGGAACCAG CCTGTGATGC TGGATGTGAC CGAGGAGCTG
 1861 AGSCCCGATC ACTTGGTGGT GGCCTGCACC CGCGCTGAGT TTGGCTCTAG CGATGAAGAT
 1921 ACAGATTGAG GTACTGAAT GTGTGGGCGT GGCTTAAGGG TGGGAAGAA TATATAAGGT
 1981 GGGGGTCTTA TGTAGTTTTG TATCTGTTTT GCAGCAGCCG CCGCCGCCAT GAGCACCAAC
 20 2041 TCGTTTGATG GAAGCATTGT GAGCTCATAT TTGACAACGC GCATGCCCCC ATGGGCCGGG
 2101 GTGCGTCAGA ATGTGATGGG CTCCAGCATT GATGGTCGCC CCGTCCTGCC CGCAAACCTCT
 2161 ACTACCTTGA CCTACGAGAC GGTGTCTGGA ACGCCGTTGG AGACTGCAGC CTCCGCCGCC
 2221 GCTTCAGCCG CTGCAGCCAC CCGCCGCGGG ATTGTGACTG ACTTTGCTTT CCTGAGCCCC
 2281 CTTGCAAGCA GTGCAGGTTT CCGTTTATCC GCGCCGATG ACAAGTTGAC GGCTCTTTTG
 25 2341 GCACAATTGG ATTCTTTGAC CCGGGAACCT AATGTCGTTT CTCAGCAGCT GTTGGATCTG
 2401 CGCCAGCAGG TTTCTGCGCT GAAGGCTTCC TCCCTCCCA ATGCGGTTTA AAACATAAAT
 2461 AAAAAACCAG ACTCTGTTTT GATTTGGATC AAGCAAGTGT CTTGCTGTCT TTATTTAGGG
 2521 GTTTTGCGCG CCGGTTAGGC CCGGACCCAG CCGTCTCGGT CGTTGAGGGT CCTGTGTATT
 2581 TTTTCCAGGA CGTGGTAAAG GTGACTCTGG ATGTTGAGAT ACATGGGCAT AAGCCCGTCT
 30 2641 CTGGGGTGGG GGTAGCACCA CTGCAGAGCT TCATGCTGCG GGGTGGTGT GTAGATGATC
 2701 CAGTCGTAGC AGGAGCCTG GGCSTGGTGC CTAATAATGT CTTTCAGTAG CAAGCTGATT
 2761 GCCAGGGGCA GGCCCTTGGT GTAAGTGTTT ACAAAGCGGT TAAGCTGGGA TGGGTGCATA
 2821 CGTGGGGATA TGAGATGCAT CTTGGACTGT ATTTTATAGT TGGCTATGTT CCCAGCCATA
 2881 TCCCTCCGGG GATTCATGTT GTGCAGAACC ACCAGCACAG TGTATCCGGT GCACTTGGGA
 35 2941 AATTTGTCAT GTAGCTTAGA AGGAAATGCG TGGAAGAAGT TGGAGACGCC CTTGTGACCT
 3001 CCAAGATTTT CCATGCATTC GTCCATAATG ATGGCAATGG GCCCACGGGC GGCGGCCTGG

3061 GCGAAGATAT TTCTGGGATC ACTAACGTCA TAGTTGTGTT CCAGGATGAG ATCGTCATAG
 3121 GCCATTTTTTA CAAAGCGCGG GCGGAGGGTG CCAGACTGCG GTATAATGGT TCCATCCGGC
 3181 CCAGGGGCGT AGTTACCCTC ACAGATTTGC ATTTCCACG CTTTGAGTTC AGATGGGGGG
 3241 ATCATGTCTA CCTGCGGGGC GATGAAGAAA ACGGTTTCCG GGGTAGGGGA GATCAGCTGG
 5 3301 GAAGAAAGCA GGTTCCTGAG CAGCTGCGAC TTACCGCAGC CGGTGGGCCC GTAAATCACA
 3361 CCTATTACCG GGTGCAACTG GTAGTTAAGA GAGCTGCAGC TGCCGTCATC CCTGAGCAGG
 3421 GGGGCCACTT CGTTAAGCAT GTCCCTGACT CGCATGTTTT CCCTGACCAA ATCCGCCAGA
 3481 AGGCGCTCGC CGCCACGCGA TAGCAGTTCT TGCAAGGAAG CAAAGTTTTT CAACGGTTTG
 3541 AGACCGTCCG CCGTAGGCAT GCTTTTGAGC GTTTGACCAA GCAGTTCCAG GCGGTCCCAC
 10 3601 AGCTCGGTCA CCTGCTCTAC GGCATCTCGA TCCAGCATAT CTCCTCGTTT CGCGGGTTGG
 3661 GCGGCTTTTC GCTGTACGGC AGTAGTCGGT GCTCCTCCAG ACGGGCCAGG GTCATGTCTT
 3721 TCCACGGGCG CAGGGTCCTC GTCAGCGTAG TCTGGGTCAC GGTGAAGGGG TGCGCTCCGG
 3781 GCTGCGCGCT GGCCAGGGTG CGCTTGAGGC TGGTCCTGCT GGTGCTGAAG CGCTGCCGGT
 3841 CTTGCGCCTG CGCGTCGGCC AGGTAGCATT TGACCATGGT GTCATAGTCC AGCCCTCCG
 15 3901 CGGCGTGGCC CTTGGCGCGC AGCTTGCCCT TGGAGGAGG GCGGCACGAG GGGCAGTGCA
 3961 GACTTTTGAG GGCGTAGAGC TTGGGCGCGA GAAATACCGA TTCCGGGGAG TAGGCATCCG
 4021 CGCGSCAGGC CCCSCAGACG GTCTCGCATT CCACGAGCCA GGTGAGCTCT GGCCGTTCSG
 4081 GGTCAAAAAC CAGGTTTCCC CCATGCTTTT TGATGCGTTT CTTACCTCTG GTTTCCATGA
 4141 GCGGCTGTCC ACGCTCGGTG ACGAAAAGGC TGTCCGTGTC CCCGTATACA GACTTGAGAG
 20 4201 GCCTGTCTC GAGCGGTGTT CCGCGGTCCT CCTCGTATAG AAACTCGGAC CACTCTGAGA
 4261 CAAAGGCTCG CGTCCAGGCC AGCAGGAAGG AGGCTAAGTG GGAGGGGTAG CGGTCGTTGT
 4321 CCACTAGGGG GTCCACTCGC TCCAGGGTGT GAAGACACAT GTCGCCCTCT TCGGCATCAA
 4381 GGAAGGTGAT TGGTTTGTAG GTGTAGGCCA CSTGACCGGG TGTTCCTGAA GGGGGGCTAT
 4441 AAAAGGGGGT GGGGGCGCST TCGTCCTCAC TCTCTCCGC ATCGCTGTCT GCGAGGGCCA
 25 4501 GCTGTTGGGG TGAGTACTCC CTCTGAAAAG CGGGCATGAC TTCTGCGCTA AGATTGTCAG
 4561 TTCCAAAAA CGAGGAGGAT TTGATATTCA CCTGGCCGCG GGTGATGCCT TTGAGGGTGG
 4621 CCGCATCCAT CTGGTCAGAA AAGACAATCT TTTTGTGTG AAGCTTGGTG GCAAACGACC
 4681 CGTAGAGGGC GTTGGACAGC AACTTGGCGA TGGAGCGCAG GGTTTGGTTT TTGTCSGAT
 4741 CGGCGCGCTC CTTGGCCGCG ATGTTTAGCT GCACGATTTC GCGCGCAACG CACCGCCATT
 30 4801 CGGGAAAGAC GGTGGTGCGC TCGTCGGGCA CCAGGTGCAC GCGCCAACCG CGGTTGTGCA
 4861 GGGTGACAAG GTCAACGCTG GTGGCTACCT CTCCGCGTAG GCGCTCGTTG GTCCAGCAGA
 4921 GGCGGCCGCC CTTGCGCGAG CAGAATGGCG GTAGGGGGTC TAGCTGCGTC TCGTCCGGGG
 4981 GGTCTGCGTC CACGGTAAAG ACCCCGGGCA GCAGGCGCGC GTCGAAGTAG TCTATCTTGC
 5041 ATCCTTGCAA GTCTAGCGCC TGCTGCCATG CGCGGGCGGC AAGCGCGCGC TCGTATGGGT
 35 5101 TGAGTGGGGG ACCCCATGGC ATGGGGTGGG TGAGCGCGGA GGCGTACATG CCGCAAATGT
 5161 CGTAAACGTA GAGGGGCTCT CTGAGTATTC CAAGATATGT AGGGTAGCAT CTTCCACCGC

5221 GGATGCTGGC GCGCACGTAA TCGTATAGTT CGTGCGAGGG AGCGAGGAGG TCGGGACCGA
 5281 GGTGCTACG GCGGGGCTGC TCTGCTCGGA AGACTATCTG CCTGAAGATG GCATGTGAGT
 5341 TGGATGATAT GGTGAGACGC TGGGAGACGT TGAAGCTGGC GTCTGTGAGA CCTACCGCGT
 5401 CACGCACGAA GGAGGCGTAG GAGTCGCGCA GCTTGTTGAC CAGCTCGGCG GTGACCTGCA
 5 5461 CGTCTAGGGC GCAGTAGTCC AGGGTTTCCT TGATGATGTC ATACTTATCC TGTCCCTTTT
 5521 TTTTCCACAG CTCGCGGTTG AGGACAACT CTTGCGGGTC TTTCCAGTAC TCTTGATCG
 5581 GAAACCCGTC GGCTCCGAA CGGTAAGAGC CTAGCATGTA GAACTGGTTG ACGGCCTGGT
 5641 AGGCGCAGCA TCCCTTTTCT ACGGGTAGCG CGTATGCCTG CGCGGCCCTC CGGAGCGAGG
 5701 TGTGGGTGAG CGCAAAGGTG TCCCTGACCA TGACTTTGAG GTACTGGTAT TTGAAGTCAG
 10 5761 TGTCGTCGCA TCCGCCCTGC TCCCAGAGCA AAAAGTCCGT GCGCTTTTTG GAACGCGGAT
 5821 TTGGCAGGGC GAAGGTGACA TCSTTGAAGA GTATCTTTCC CGCGCGAGGC ATAAAGTTGC
 5881 GTGTGATGCG GAAGGGTCCC GGCACCTCGG AACGGTTGTT AATTACCTGG GCGGCGAGCA
 5941 CGATCTCGTC AAAGCCGTTG ATGTTGTGGC CCACAATGTA AAGTTCCAAG AAGCGCGGGA
 6001 TGCCCTTGAT GGAAGGCAAT TTTTAAAGTT CCTCGTAGGT GAGCTCTTCA GGGGAGCTGA
 15 6061 GCGCGTCTC TGAAGGGGCC CAGTCTGCAA GATGAGGGTT GGAAGCGACG AATGAGCTCC
 6121 ACAGGTCACG GGCCATTAGC ATTTGCAGGT GGTGCGGAAA GGTCCATAAC TGGCGACCTA
 6181 TGGCCATTTT TTCTGGGGTG ATGCACTAGA AGGTAAGCGG GTCTTGTTC CAGCGGTCCC
 6241 ATCCAAGGTT CGCGGCTAGG TCTCGCGCGG CAGTCACTAG AGGCTCATCT CCGCCGAACT
 6301 TCATGACCAG CATGAAGGGC ACGAGCTGCT TCCCAAAGGC CCCCATCCAA GTATAGGTCT
 20 6361 CTACATCGTA GGTGACAAAG AGACGCTCGG TGCGAGGATG CGAGCCGATC GGGAGAAGT
 6421 GGATCTCCCG CCACCAATTG GAGGAGTGGC TATTGATGTG GTGAAAGTAG AAGTCCCTGC
 6481 GACGGGCCGA ACACTCGTGC TGGCTTTTGT AAAACGTGC GCAGTACTGG CAGCGGTGCA
 6541 CGGGCTGTAC ATCCTGCACG AGGTTGACCT GACGACCGCG CACGAGGAAG CAGAGTGGGA
 6601 ATTTGAGCCC CTCGCTGGC GGGTTTGGCT GGTGGTCTTC TACTTCGGCT GCTTGTCTTT
 25 6661 GACCGTCTGG CTGCTCGAGG GGAGTTACGG TGGATCGGAC CACCACGCCG CGCGAGCCCA
 6721 AAGTCCAGAT GTCCGCGCGC GCGGTCGGA GCTTGATGAC AACATCGCGC AGATGGGAGC
 6781 TGTCCATGGT CTGGAGCTCC CGCGGCGTCA GGTGAGGCGG GAGCTCCTGC AGGTTTACCT
 6841 CGCATAGACG GGTGAGGGCG CGGGCTAGAT CCAGGTGATA CCTAATTTCC AGGGGCTGGT
 6901 TGGTGGCGGC GTCGATGGCT TGCAAGAGGC CGCATCCCCG CGGCGCGACT ACGGTACCGC
 30 6961 GCGGCGGGCG GTGGGCGCGG GGGGTGTCCT TGGATGATGC ATCTAAAAGC GGTGACGCGG
 7021 GCGAGCCCCC GGAGGTAGGG GGGGCTCCGG ACCCGCCGGG AGAGGGGGCA GGGGCACGTC
 7081 GGCGCGCGCG GCGGGCAGGA GCTGGTGCTG CGCGCGTAGG TTGCTGGCGA ACGCGACGAC
 7141 GCGGCGGTTG ATCTCCTGAA TCTGGCGCCT CTGCGTGAAG ACGACGGGCC CGGTGAGCTT
 7201 GAGCCTGAAA GAGAGTTCSA CAGAATCAAT TTCGGTGTCTG TTGACGGCGG CCTGGCGCAA
 35 7261 AATCTCCTGC ACGTCTCCTG AGTTGTCTTG ATAGGCGATC TCGGCCATGA ACTGCTCGAT
 7321 CTCTTCCTCC TGGAGATCAA TTGAAGCTAG CTTTAATGCG GTAGTTTATC ACAGTTAAAT

7381 TGCTAACGCA GTCAGGCACC GTGTATGAAA TCTAACAATG CGCTCATCGT CATCCTCGGC
 7441 ACCGTCACCC TGGATGCTGT AGGCATAGGC TTGGTTATGC CGGTAAGTCC GGGCCTCTTG
 7501 CGGGATATCG TCCATTCCGA CAGCATCGCC AGTCACTATG GCGTGCTGCT AGCGCTATAT
 7561 GCGTTGATGC AATTTCTATG CGCACCCGTT CTCGGAGCAC TGTCCGACCG CTTTGGCCCG
 5 7621 CGCCCAGTCC TGCTCGCTTC GCTACTTGGA GCCACTATCG ACTACGCGAT CATGGCGACC
 7681 ACACCCGTCC TGTGGATCTC GACCGATGCC CTTGAGAGCC TTCAACCCAG TCAGCTCCTT
 7741 CCGGTGGGCG CGGGGCATGA CTATCGTCGC CGCACTTATG ACTGTCTTCT TTATCATGCA
 7801 ACTCGTAGGA CAGGTGCCGG CAGCGCTCTG GGTCAATTTT GGCAGGAGCC GCTTTCGCTG
 7861 GAGCGCGACG ATGATCGGCC TGTGCTTGC GGTATTCGGA ATCTTGCACG CCCTCGCTCA
 10 7921 AGCCTTCGTC ACTGGTCCCG CCACCAAACG TTTCGGCGAG AAGCAGGCCA TTATCGCCCG
 7981 CATGGCGGCC GACGCGCTGG GCTACGTCTT GCTGGCGTTC GCGACGCGAG GCTGGATGGC
 8041 CTTCCCCATT ATGATTCTTC TCGCTTCGGG CGGCATCGGG ATGCCCGCGT TGCAGGCCAT
 8101 GCTGTCCAGG CAGGTAGATG ACGACCATCA GGGACAGCTT CAAGGATCGC TCGCGGCTCT
 8161 TACCAGCCCA GCAAAAGGCC AGGAACCGTA AAAAGGCCGC GTTGCTGGCG TTTTTCATA
 15 8221 GGCTCCGCCC CCCTGACGAG CATCACAAA ATCGACGCTC AAGTCAGAGG TGGCGAAACC
 8281 CGACAGGACT ATAAAGATAC CAGGCGTTTC CCCCTGGAAG CTCCCTCGTG CGCTCTCCTG
 8341 TTCCGACCCT GCGGCTTACC GGATACCTGT CCGCCTTTCT CCCTTCGGGA AGCGTGGGCG
 8401 TTTCTCATAG CTCACGCTGT AGGTATCTCA GTTCGGTGTA GGTGCTTCGC TCCAAGCTGG
 8461 GCTGTGTGCA CGAACCCCCC GTTCAGCCCG ACCGCTGCGC CTTATCCGGT AACTATCGTC
 20 8521 TTGAGTCCAA CCGGTAAGA CACGACTTAT CGCCACTGGC AGCAGCCACT GGTAACAGGA
 8581 TTAGCAGAGC GAGGTATGTA GCGGGTGCTA CAGAGTTCTT GAAGTGGTGG CCTAACTACG
 8641 GCTACACTAG AAGGACAGTA TTTGGTATCT GCGCTCTGCT GAAGCCAGTT ACCTTCGGAA
 8701 AAAGAGTTGG TAGCTCTTGA TCCGGCAAAC AAACCAACGC TGGTAGCGGT GGTTTTTTTG
 8761 TTTGCAAGCA GCAGATTACG CGCAGAAAAA AAGGATCTCA AGAAGATCCT TTGATCTTTT
 25 8821 CTACGGGGTC TGACGCTCAG TGGAAACGAA ACTCACGTTA AGGGATTTTG GTCATGAGAT
 8881 TATCAAAAAG GATCTTCACC TAGATCCTTT TAAATTAAAA ATGAAGTTTT AAATCAATCT
 8941 AAAGTATATA TGAGTAACCT TGGTCTGACA GTTACCAATG CTTAATCAGT GAGGCACCTA
 9001 TCTCAGCGAT CTGTCTATTT CGTTCATCCA TAGTTGCCTG ACTCCCCGTC GTGTAGATAA
 9061 CTACGATACG GGAGGGCTTA CCATCTGGCC CCAGTGCTGC AATGATACCG CGAGACCCAC
 30 9121 GCTCACCGGC TCCAGATTTA TCAGCAATAA ACCAGCCAGC CGGAAGGGCC GAGCGCAGAA
 9181 GTGGTCCCTGC AACTTTATCC GCCTCCATCC AGTCTATTAA TTGTTGCCGG GAAGCTAGAG
 9241 TAAGTAGTTC GCCAGTTAAT AGTTTGCGCA ACGTTGTTGC CATTGCTGCA GGCATCGTGG
 9301 TGTCACGCTC GTCGTTTGGT ATGGCTTCAT TCAGCTCCGG TTCCCAACGA TCAAGGCGAG
 9361 TTACATGATC CCCCATGTTG TGCAAAAAG CGGTTAGCTC CTTCGGTCCT CCGATCGTTG
 35 9421 TCAGAAGTAA GTTGGCCGCA GTGTTATCAC TCATGGTTAT GGCAGCACTG CATAATTCTC
 9481 TTAAGTGCAT GCCATCCGTA AGATGCTTTT CTGTGACTGG TGAGTACTCA ACCAAGTCAT

9541 TCTGAGAATA GTGTATGCGG CGACCGAGTT GCTCTTGCCC GGC GTCAACA CGGGATAATA
9601 CCGCGCCACA TAGCAGAACT TTAAAAGTGC TCATCATTGG AAAACGTTCT TCGGGGCGAA
9661 AACTCTCAAG GATCTTACCG CTGTTGAGAT CCAGTTCGAT GTAACCCACT CGTGCACCCA
9721 ACTGATCTTC AGCATCTTTT ACTTTCACCA GCGTTTCTGG GTGAGCAAAA ACAGGAAGGC
5 9781 AAAATGCCGC AAAAAAGGGA ATAAGGGCGA CACGGAAATG TTGAATACTC ATACTCTTCC
9841 TTTTTC AATA TTATTGAAGC ATTTATCAGG GTTATTGTCT CATGAGCGGA TACATATTTG
9901 AATGTATTTA GAAAAATAAA CAAATAGGGG TTCCGCGCAC ATTTCCCCGA AAAGTGCCAC
9961 CTGACGTCTA AGAAACCAT ATTATCATGA CATTAAACCTA TAAAAATAGG CGTATCACGA
10021 GGCCCTTTTCG TCTTCAAGAA TTCTCATGTT TGACAGCTTA TCATCATCAA TAATATACCT
10 10081 TATTTTGGAT TGAAGCCAT ATGATAATGA GGGGGTGGAG TTTGTGACGT GGC GCGGGGC
10141 GTGGGAACGG GCGGGGTGAC GTAGTAGTGT GCGGAAGTG TGATGTTGCA AGTGTGGCGG
10201 AACACATGTA AGCGACGGAT GTGGCAAAAG TGACGTTTTT GGTGTGCGCC GGTGTACACA
10261 GGAAGTGACA ATTTTCGCGC GGTTTTAGGC GGATGTTGTA GTAAATTTGG GCGTAACCGA
10321 GTAAGATTTG GC

Claims

1. A recombinant nucleic acid molecule comprising a vector useful for transfection or transduction of mammalian, e.g. human, cells, wherein said vector contains a nucleic acid insertion encoding an expressible hybrid polypeptide or protein which comprises a domain with a binding function and a domain with an effector function.
2. A recombinant nucleic acid molecule according to Claim 1, wherein said domain with a binding function comprises a receptor binding domain.
3. A recombinant nucleic acid molecule according to Claim 2, wherein said receptor binding domain is selected from the group consisting of urokinase receptor binding domain of urokinase, receptor binding domain of epidermal growth factor, receptor associated protein that binds to LDL Receptor related protein (α_2 -macroglobulin receptor) and VLDL Receptor.
4. A recombinant nucleic acid molecule according to Claim 2, wherein said receptor binding domain comprises the aminoterminal part of urokinase which is capable of binding to the urokinase receptor.
5. A recombinant nucleic acid molecule according to Claim 2, wherein said receptor binding domain comprises amino acid residues 1 through 135 of urokinase.
6. A recombinant nucleic acid molecule according to Claim 1, wherein said domain with an effector function is an enzymatically active domain.
7. A recombinant nucleic acid molecule according to Claim 1, wherein said domain with an effector function has protease inhibitor activity.
8. A recombinant nucleic acid molecule according to Claim 7, wherein said domain having protease inhibitor activity comprises a protease inhibitor or active part

thereof, said protease inhibitor being selected from the group consisting of (bovine) pancreatic trypsin inhibitor, (bovine) splenic trypsin inhibitor, urinary trypsin inhibitor, tissue inhibitor of matrix metalloproteinase 1, tissue inhibitor of matrix metalloproteinase 2, tissue inhibitor of matrix metalloproteinase 3, and elastase inhibitor.

9. A recombinant nucleic acid molecule according to Claim 7, wherein said domain having protease inhibitor activity comprises (amino acid residues 53 through 94 of) mature bovine pancreatic trypsin inhibitor.

10. A recombinant nucleic acid molecule according to Claim 7, wherein said domain having protease inhibitor activity comprises bovine splenic trypsin inhibitor.

11. A recombinant nucleic acid molecule according to Claim 7, wherein said domain having protease inhibitor activity comprises a tissue inhibitor of matrix metalloproteinases.

12. A recombinant nucleic acid molecule according to Claim 1, wherein said domain with an effector function comprises (an active part of) two or more different protease inhibitors, or two or more copies of (an active part of) a protease inhibitor, or both.

13. A recombinant nucleic acid molecule according to Claim 1, wherein said vector is selected from the group consisting of viral and non-viral vectors useful for transfection or transduction of mammalian cells.

14. A recombinant nucleic acid molecule according to Claim 1, wherein said vector is an adenovirus vector or a retrovirus vector useful for transfection or transduction of human cells.

15. A recombinant nucleic acid molecule according to Claim 1, wherein said vector is an adenovirus vector based on shuttle vector pMAD5.

16. A recombinant nucleic acid molecule according to Claim 1, wherein said nucleic acid insertion encoding an

expressible hybrid polypeptide or protein is under the control of a cell- or tissue-specific promoter.

17. A recombinant nucleic acid molecule according to Claim 1, wherein said nucleic acid insertion encoding an expressible hybrid polypeptide or protein is under the control of an endothelial cell-specific promoter, or a vascular smooth muscle cell-specific promoter, or a liver-specific promoter.

18. A process for preventing local proteolytic activity, extracellular matrix degradation, cell migration, cell invasion, or tissue remodeling, comprising transfecting or transducing the cells involved or cells in their environment with a recombinant nucleic acid molecule as claimed in any one of the preceding Claims to obtain local expression of the hybrid polypeptide or protein encoded by said nucleic acid molecule.

19. A process for producing a hybrid polypeptide or protein which comprises a domain with a binding function and a domain with an effector function, comprising transfecting or transducing mammalian cells with a recombinant nucleic acid molecule as claimed in any one of Claims 1 to 17 to obtain expression of the hybrid polypeptide or protein encoded by said nucleic acid molecule, and optionally recovering the hybrid polypeptide or protein produced.

Title: Method and Construct for inhibition of cell migration

Abstract

A recombinant nucleic acid molecule comprising a vector useful for transfection or transduction of mammalian cells, wherein said vector contains a nucleic acid insertion encoding an expressible hybrid polypeptide or protein which comprises a domain with a binding function and a domain with an effector function. The domain with a binding function may comprise a receptor binding domain, and the domain with an effector function may have enzymatic activity, in particular protease inhibitor activity. The vector may be a viral (e.g. adenovirus or retrovirus) or non-viral vector useful for transfection or transduction of mammalian cells. The nucleic acid insertion encoding an expressible hybrid polypeptide or protein may be under the control of a cell- or tissue-specific promoter.

A process for preventing local proteolytic activity, extracellular matrix degradation, cell migration, cell invasion, or tissue remodeling, comprising transfecting or transducing the cells involved or cells in their environment with the recombinant nucleic acid molecule to obtain local expression of the hybrid polypeptide or protein encoded thereby.

A process for producing the hybrid polypeptide or protein by transfecting or transducing mammalian cells with the recombinant nucleic acid molecule to obtain expression and optionally recovering the hybrid polypeptide or protein produced.




Fig. 1




Fig. 2




Fig. 3



Fig. 4